A novel phosphodiesterase inhibitor for the treatment of chronic liver injury and metabolic diseases.

Dalton W Staller Sanjali S Panigrahi Yahani P Jayasinghe Yuxiang Dong Sohan Mahto Virender Kumar Donald R Ronning Ram I Mahato

Published in: Hepatology (Baltimore, Md.) (2024)

In conclusion, we synthesized and demonstrated that MDL3, a novel phosphodiesterase 4B and PDE5A inhibitor, presents a promising avenue of exploration for treating chronic liver disease.

Keyphrases

liver injury
drug induced